17338-96-4

Basic information

• Product Name: 8-METHYLXANTHINE
• Synonyms: 8-METHYLXANTHINE;2,6-DIHYDROXY-8-METHYLPURINE;3,7-dihydro-8-methyl-1H-purine-2,6-dione;8-Methyl-1H-purine-2,6(3H,7H)-dione
• CAS NO: 17338-96-4
• Molecular Formula: C₆H₆N₄O₂
• Molecular Weight: 166.14
• EINECS: 241-362-1
• Mol File: 17338-96-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.522 g/cm³
• Refractive Index: 1.882
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly)
• CAS DataBase Reference: 8-METHYLXANTHINE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-METHYLXANTHINE(17338-96-4)
• EPA Substance Registry System: 8-METHYLXANTHINE(17338-96-4)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 17338-96-4(Hazardous Substances Data)

Usage

Purification Methods

Crystallise it from water. [Beilstein 26 III/IV 2330.]

InChI:InChI=1/C6H6N4O2/c1-2-7-3-4(8-2)9-6(12)10-5(3)11/h3H,1H3,(H2,7,8,9,10,11,12)

Upstream product

• 108-24-7 acetic anhydride 
• 3240-72-0 5,6-diaminouracil 
• 90877-70-6 ethyl 2-acetamido-2-cyanoacetate 
• 110-86-1 pyridine 
• 69-93-2 uric Acid 
• 60-35-5 acetamide 
• 3240-72-0 5,6-diaminouracil 
• 94216-88-3 6-acetylamino-5-(diacetylamino)-pyrimidine-2,4<1H,3H>dione 
• 7732-18-5 water 
• 5435-16-5 5-sulfaminouracil 
• 10184-01-7 5-acetylamino-6-amino-1H-pyrimidine-2,4-dione 
• 121-69-7 N,N-dimethyl-aniline 
• 91-22-5 quinoline 

Downstream Products

• 61066-33-9 pyrimidine-2,4,5,6(1H,3H)-tetraone 
• 143-37-3 acetamidine 
• 57476-37-6 2,6-dichloro-8-methyl-9H-purine 
• 144-62-7 oxalic acid 
• 832-66-6 8-methylcaffeine 
• 6050-42-6 3,7,8-trimethyl-3,7-dihydro-purine-2,6-dione 
• 3051-09-0 ammonium 5-(2,4,6-trioxoperhydropyrimidin-5-ylideneamino)barbiturate 

Relevant articles and documents

Synthesis and biological properties of C-2, C-8, N-9 substituted 6-(3-chloroanilino)-purine derivatives as cyclin-dependent kinase inhibitors. Part II

In this study, C-2, C-8, N-9 substituted 6-(3-chloroanilino)purine derivatives were synthesized and their inhibitory effects on cyclin-dependent kinases (CDK2, 4) as well as their cytotoxicities were evaluated. The effects of substituents at the C-2, C-8, and N-9 positions of the substituted purine were investigated. Among the compounds tested, [6-(3-chloroanilino)-2-(2-hydroxymethyl-4-hydroxypyrrolidyl)- 9-isopropylpurine] (4h) was the most active inhibitor of CDK2 with IC50 of 0.3μM i.e. a two-fold increased inhibitory activity as compared to roscovitine. Results from structure-activity relationship studies should allow the design of more potent and selective CDK2 inhibitors, which may provide an effective therapy for cancer or other CDK-dependent diseases.